Low serum Metrnl levels are associated with increased risk of sarcopenia in the older adults

Zhi-Yue Wang,Yi-Min Li,Jian-Jun Yan,Quan Wang,Can Zhao,Xiang Lu,Zheng-Kai Shen,Jin-Shui Xu,Wei Gao
DOI: https://doi.org/10.1007/s41999-024-01074-y
2024-10-04
European Geriatric Medicine
Abstract:To investigate the association of serum Metrnl levels with the risk and severity of sarcopenia in a Chinese population of community-dwelling older adults. Our present study showed for the first time that serum Metrnl was positively correlated with the components of sarcopenia, including skeletal muscle mass, grip strength, and gait speed. Low serum Metrnl level (< 197.2 pg/mL) was associated with increased risk of sarcopenia in the older adults. Addition of Metrnl to the traditional screening tools may help to facilitate the risk stratification for the patients with sarcopenia. Sarcopenia is a geriatric syndrome characterized by progressive loss of muscle mass and function. Meteorin-like (Metrnl) is a secretory protein that has protective effects on skeletal muscle injury. However, the association of Metrnl level with sarcopenia remains unclear. A total of 772 community-dwelling older adults (median age = 76 years), comprising 409 males and 363 females, from both urban and rural areas were enrolled. Serum Metrnl was measured by enzyme-linked immunosorbent assay. Appendicular skeletal muscle mass index (ASMI), grip strength, and gait speed were measured for the assessment of sarcopenia. We found that serum Metrnl levels were lower in patients with sarcopenia [median (IQR) = 180.1 (151.3–220.3) pg/mL] than older adults without sarcopenia [211.9 (163.2–270.0) pg/mL, P < 0.001]. Receiver-operating characteristic curve analysis showed that the optimal cut-off value of serum Metrnl level that predicted sarcopenia was 197.2 pg/mL with a sensitivity of 59.2% and a specificity of 63.8% (AUC = 0.63, 95% CI = 0.59–0.67, P < 0.001). Multivariate logistic regression analyses showed that lower serum Metrnl level (< 197.2 pg/mL) was significantly associated with increased risk of sarcopenia (adjusted OR = 2.358, 2.36, 95% CI = 1.528–3.685, P < 0.001). Moreover, serum Metrnl concentration was positively correlated with the components of sarcopenia including ASMI (r = 0.135, P < 0.001), grip strength (r = 0.102, P = 0.005), and gait speed (r = 0.106, P = 0.003). Taken together, our findings demonstrate that low serum Metrnl level is correlated with increased risk of sarcopenia in the older adults.
geriatrics & gerontology,gerontology
What problem does this paper attempt to address?